Last reviewed · How we verify

Best standard of care (BSoC)

Bayer · Phase 3 active Small molecule

Best standard of care (BSoC) is a Small molecule drug developed by Bayer. It is currently in Phase 3 development.

Best standard of care (BSoC) is a comparator arm designation used in clinical trials, not a drug with a specific mechanism of action.

At a glance

Generic nameBest standard of care (BSoC)
SponsorBayer
ModalitySmall molecule
PhasePhase 3

Mechanism of action

BSoC refers to the established, most effective treatment regimen available for a given condition at the time of trial design. It serves as the control or comparator arm against which investigational drugs are evaluated. The specific mechanism depends entirely on what treatments constitute standard care for the indication being studied.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Best standard of care (BSoC)

What is Best standard of care (BSoC)?

Best standard of care (BSoC) is a Small molecule drug developed by Bayer.

How does Best standard of care (BSoC) work?

Best standard of care (BSoC) is a comparator arm designation used in clinical trials, not a drug with a specific mechanism of action.

Who makes Best standard of care (BSoC)?

Best standard of care (BSoC) is developed by Bayer (see full Bayer pipeline at /company/bayer).

What development phase is Best standard of care (BSoC) in?

Best standard of care (BSoC) is in Phase 3.

Related